First in the world: Innovative treatment for uterine fibroids approved by EU
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
First in the world: Innovative treatment for uterine fibroids approved by EU
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
First in the world: Innovative treatment for uterine fibroids approved by EU.
On June 18, ObsEva and Theramex jointly announced that the European Commission (EC) granted marketing authorization for the oral gonadotropin-releasing hormone (GnRH) antagonist Yselty (linzagolix).
According to the press release, Yselty will be the first in the EU to treat adult female patients of reproductive age with moderate to severe uterine fibroids with or without concomitant hormonal add-back therapy ( >18 years) medicines.
Uterine fibroids are a common benign uterine muscle tissue tumor that occurs in about 25% of women of reproductive age.
Fibroids vary in size and can cause symptoms of varying degrees, such as heavy bleeding during menstruation, anemia, flatulence, frequent urination, pain, etc., which seriously affect the quality of life.
Sometimes it even causes anxiety, pain and psychological problems. Many patients with severe symptoms even require surgery.
Yselty is an oral, once-daily GnRH antagonist. Yselty was developed to give patients flexibility when choosing a dose.
Regardless of whether patients with uterine fibroids themselves received endocrine reverse add-on therapy.
Yselty offers a potential “best-in-class” efficacy and tolerability for women receiving endocrine reverse add-on therapy.
For those patients who are unable or unwilling to receive endocrine reverse add-on therapy, this drug is the first oral GnRH antagonist in the EU that can be used without endocrine reverse add-on therapy. The U.S. FDA is currently reviewing a New Drug Application (NDA) for linzagolix.
▲ Molecular formula of Linzagolix (Image source: Ed (Edgar181), Public domain, via Wikimedia Commons)
The marketing approval for Yselty is based on positive results from two PRIMROSE Phase 3 studies.
Combination trial data at week 24 showed efficacy in 84.5% of women who received 200 mg of Yselty and concurrent endocrine reverse add-on therapy.
Among those women who received 100 mg of Yselty without concomitant endocrine reverse add-on therapy, 56.5 percent achieved remission.
“As the first GnRH antagonist that can be used with or without concurrent endocrine reverse add-on therapy, Yselty has the potential to transform the treatment of women with uterine fibroids,” said Dr. Brandi Howard, Chief Clinical Medical Officer of ObsEva. “We are delighted that Yselty is the first alternative option for physicians and the millions of women who are unable or unable to receive endocrine reverse add-on therapy.”
References:
[1] ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids. Retrieved June 17, 2022 from https://www.obseva.com/pressrelease-detail/?pr =5038
[2] Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids. Retrieved June 17, 2022 from https://www.theramex.com/news/theramex- announces-european-commission-marketing-authorization-for-yselty-linzagolix-an-oral-gnrh-antagonist-for-the-treatment-of-symptoms-of-uterine-fibroids/
First in the world: Innovative treatment for uterine fibroids approved by EU
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.